Intellia Therapeutics (NTLA) Prices 4.1M Share Offering at $145/sh

Intellia Therapeutics (NTLA) Extends Gain, Up 15%

June 29, 2021 3:24 PM EDT

Intellia Therapeutics (NASDAQ: NTLA) Extends Gain, Up 15%

... More

Pre-Open Stock Movers 06/29: (CERE) (CNSP) (VERB) Higher; (DMAC) (CELC) (ALGS) Lower (more...)

June 29, 2021 9:27 AM EDT

Pre-Open Stock Movers:

Cerevel Therapeutics (Nasdaq: CERE) 59% HIGHER; announced... More

Intellia Therapeutics (NTLA) PT Raised to $168 at Raymond James

June 29, 2021 7:14 AM EDT

Raymond James analyst Steven Seedhouse raised the price target on Intellia Therapeutics (NASDAQ: NTLA) to $168.00 (from $106.00) while maintaining a Outperform rating.... More

Intellia Therapeutics (NTLA) PT Raised to $150 at RBC Capital

June 29, 2021 6:09 AM EDT

RBC Capital analyst Luca Issi raised the price target on Intellia Therapeutics (NASDAQ: NTLA) to $150.00 (from $110.00) while maintaining a Outperform rating.... More

Intellia Therapeutics (NTLA) PT Raised to $125 at Oppenheimer

June 28, 2021 6:49 PM EDT

Oppenheimer analyst Jay Olson raised the price target on Intellia Therapeutics (NASDAQ: NTLA) to $125.00 (from $73.00) while maintaining a Perform rating.

... More

After-Hours Stock Movers 06/28: (LIVX) (MS) (GS) Higher; (CELC) (BTRS) (ALGS) Lower (more...)

June 28, 2021 6:48 PM EDT

After-Hours Stock Movers

Celcuity Inc. (Nasdaq: CELC) 15.2% LOWER; announced that it has commenced an underwritten public offering of shares of its common stock.

BTRS Holdings Inc. (Nasdaq: BTRS) 7.2% LOWER; announced the commencement of an underwritten secondary offering of 9,000,000 shares of the Companys Class 1 common stock.

Aligos Therapeutics, Inc. (Nasdaq: ALGS) 6.6% LOWER; today announced that it has commenced an underwritten public offering of... More

Intellia Therapeutics (NTLA) Announces $400M Proposed Offering

June 28, 2021 4:02 PM EDT

Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today that it has commenced an underwritten public offering of $400 million of shares of its common stock. Intellia also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by... More

Intellia Therapeutics (NTLA) PT Raised to $160 at JMP Securities, Following Clinical Business Update

June 28, 2021 2:37 PM EDT

JMP Securities analyst Silvan Tuerkcan raised the price target on Intellia Therapeutics (NASDAQ: NTLA) to $160.00 (from $88.00) while maintaining a Market Outperform rating.

... More

Intellia Therapeutics (NTLA) PT Raised to $159 at SVB Leerink, Following Clinical Business Update

June 28, 2021 2:06 PM EDT

SVB Leerink analyst Mani Foroohar raised the price target on Intellia Therapeutics (NASDAQ: NTLA) to $159.00 (from $81.00) while maintaining a Outperform rating.

... More

Intellia Therapeutics (NTLA) PT Raised to $130 at Chardan Capital Markets

June 28, 2021 11:35 AM EDT

Chardan Capital Markets analyst Geulah Livshits raised the price target on Intellia Therapeutics (NASDAQ: NTLA) to $130.00 (from $85.00) while maintaining a Buy rating.

... More

Intellia Therapeutics (NTLA) PT Raised to $130 at Wedbush, Following Clinical Business Update

June 28, 2021 11:29 AM EDT

Wedbush analyst David Nierengarten raised the price target on Intellia Therapeutics (NASDAQ: NTLA) to $130.00 (from $87.00) while maintaining a Neutral rating.

... More

Increasing unusual put option volume: QRTEA NTLA FNV WISH CCXI PSAC KNDI ASAN SIX

June 28, 2021 10:47 AM EDT

Increasing unusual put option volume: QRTEA NTLA FNV WISH CCXI PSAC KNDI ASAN SIX

... More

Intellia Therapeutics (NTLA) call put ratio 1 call to 1.1 puts after interim data from Phase 1 study of NTLA-2001

June 28, 2021 10:36 AM EDT

Intellia Therapeutics (NASDAQ: NTLA) 30-day option implied volatility is at 88; compared to its 52-week range of 56 to 147. Call put ratio 1 call to 1.1 puts after interim data from Phase 1 study of NTLA-2001.

... More

Intellia Therapeutics (NTLA) call put ratio 1 call to 1.1 puts as shares rally 45%

June 28, 2021 10:16 AM EDT

Intellia Therapeutics (NASDAQ: NTLA) 30-day option implied volatility is at ; compared to its 52-week range of 56 to 147. Call put ratio 1 call to 1.1 puts after interim data from Phase 1 study of NTLA-2001.

... More

Pre-Open Stock Movers 06/28: (NTLA) (AVXL) (EDIT) Higher; (GTEC) (XPO) (CCL) Lower (more...)

June 28, 2021 9:28 AM EDT

Pre-Open Stock Movers:

Intellia Therapeutics, Inc. (NASDAQ: NTLA) 56% HIGHER; Intellia and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive interim data from an ongoing Phase 1 clinical study of their lead in vivo genome editing candidate, NTLA-2001, which is being developed as a single-dose treatment for transthyretin (ATTR) amyloidosis. The Phase 1 study, run by Intellia as the program's development and commercialization lead, is evaluating NTLA-2001 in people living with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). NTLA-2001 is the first CRISPR/Cas9-based... More

Intellia Therapeutics (NTLA) PT Raised to $110 at Roth Capital After First In-Person Data with a Clean Safety Profile

June 28, 2021 9:25 AM EDT

Roth Capital analyst Tony Butler raised the price target on Intellia Therapeutics (NASDAQ: NTLA) to $110.00 after a presentation by Dr. Julian Gilmore of University College London at the 2021 Peripheral Nerve Society meeting highlighted the first-in-human data from the NTLA-2001 program demonstrated... More

Intellia Therapeutics (NTLA) call put ratio 1.7 calls to 1 put into interim data from Phase 1 study of NTLA-2001

June 28, 2021 9:25 AM EDT

Intellia Therapeutics (NASDAQ: NTLA) call put ratio 1.7 calls to 1 put into interim data from Phase 1 study of NTLA-2001

... More

'Knocks It Out Of The Park': Intelia (NTLA) Explodes 50% After Publishing Positive Phase 1 Results For Its Leading Genome Editing Candidate, Analyst Raises PT by 100%

June 28, 2021 8:59 AM EDT

Intellia Therapeutics, Inc. (NASDAQ: NTLA) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) published today positive preliminary data from an ongoing Phase 1 clinical study of their lead in vivo genome editing candidate NTLA-2001.

The 2001 candidate is being developed as a single-dose therapy for transthyretin (ATTR) amyloidosis, a modestly progressive disease characterized by the buildup of very high deposits of an amyloid protein.

This is a landmark study as NTLA-2001 is the first CRISPR/Cas9-based therapy candidate to be administered systemically, via intravenous infusion, for precision... More

Goldman Sachs Encouraged by Regeneron Pharma's (REGN) First Human Gene Editing Data

June 28, 2021 6:30 AM EDT

Goldman Sachs analyst Terence Flyn reiterated a Buy rating and $814.00 price target on Conviction List name, Regeneron Pharma (NASDAQ: REGN) after the company, in conjunction with Intellia Therapeutics (NASDAQ: NTLA) presented (at PNS conference) and published (in New England... More

Intellia Therapeutics (NTLA) PT Raised to $171 at H.C. Wainwright

June 28, 2021 6:21 AM EDT

H.C. Wainwright analyst Michael G. King, Jr. raised the price target on Intellia Therapeutics (NASDAQ: NTLA) to $171.00 (from $111.00) while maintaining a Buy rating.... More

Intellia Therapeutics (NTLA), Regeneron (REGN) Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy f

June 28, 2021 6:08 AM EDT

First-ever clinical data supporting safety and efficacy of in vivo CRISPR genome editing in humansInterim readout in ongoing Phase 1 trial finds single 0.3 mg/kg dose of NTLA-2001 led to 87% mean reduction in serum TTR, with a maximum 96% serum TTR reduction by day 28, with dose-dependent responseEncouraging safety profile; no serious adverse events observed in the first six patients by day 28Data published in The New England Journal of Medicine and presented at Peripheral Nerve Society Annual Meeting (PNS)Intellia to host investor event on... More

Intellia Therapeutics (NTLA) PT Raised to $160 at Truist Securities

June 28, 2021 2:02 AM EDT

Truist Securities analyst Joon Lee raised the price target on Intellia Therapeutics (NASDAQ: NTLA) to $160.00 (from $80.00) while maintaining a Buy rating.... More